Intercept Pharma (ICPT) Receives Final Approval for Securities Class Action Settlement

September 12, 2016 6:19 AM EDT

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

Intercept Pharma (Nasdaq: ICPT) disclosed the following in a U.S. SEC filing on Monday:

Item 8.01 Other Events.

On September 8, 2016, the U.S. District Court for the Southern District of New York (the “Court”) granted final approval of the previously announced agreement with the lead plaintiff to settle the purported securities class action litigation, styled In re: Intercept Pharmaceuticals, Inc. Securities Litigation, against Intercept Pharmaceuticals, Inc. (the “Company” or “Intercept”) and certain of its officers.

The settlement included the payment of $55 million, of which $10 million was funded by the Company’s insurers. The defendants do not admit any liability as part of the settlement.

The final judgment and order of the Court included a dismissal of the action with prejudice against all defendants.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Litigation

Add Your Comment